OECD-based pricing guideline should be introduced, lawmaker suggests

Published: 2004-10-12 06:59:00

Updated: 2004-10-12 06:59:00

The government needs to re-evaluate the current pricing-set system of reimbursable drugs and introduce a new OECD-based pricing guideline to discourage the increasing prescription patter toward high-priced drug and protect the domestic pharmaceutical industry, said Rep. Hyun Ae-ja of Democratic L...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK